ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
Europe - FRA:ZEG - GB0009895292 - Common Stock
154.25 EUR
+0.45 (+0.29%)
Overall ZEG gets a fundamental rating of 5 out of 10. We evaluated ZEG against 54 industry peers in the Pharmaceuticals industry. ZEG scores excellent on profitability, but there are concerns on its financial health. ZEG is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year ZEG was profitable.
ZEG had a positive operating cash flow in the past year.
ZEG had positive earnings in each of the past 5 years.
In the past 5 years ZEG always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of 8.21%, ZEG is doing good in the industry, outperforming 64.81% of the companies in the same industry.
With a decent Return On Equity value of 20.48%, ZEG is doing good in the industry, outperforming 68.52% of the companies in the same industry.
With a decent Return On Invested Capital value of 14.42%, ZEG is doing good in the industry, outperforming 72.22% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for ZEG is below the industry average of 14.51%.
The 3 year average ROIC (11.62%) for ZEG is below the current ROIC(14.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
Looking at the Profit Margin, with a value of 16.17%, ZEG is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
ZEG's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 24.34%, ZEG is in the better half of the industry, outperforming 62.96% of the companies in the same industry.
ZEG's Operating Margin has improved in the last couple of years.
ZEG has a better Gross Margin (81.90%) than 83.33% of its industry peers.
ZEG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
ZEG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for ZEG remains at a similar level compared to 1 year ago.
ZEG has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ZEG has a worse debt to assets ratio.
2.2 Solvency
ZEG has an Altman-Z score of 5.85. This indicates that ZEG is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.85, ZEG belongs to the top of the industry, outperforming 81.48% of the companies in the same industry.
The Debt to FCF ratio of ZEG is 3.41, which is a good value as it means it would take ZEG, 3.41 years of fcf income to pay off all of its debts.
ZEG's Debt to FCF ratio of 3.41 is in line compared to the rest of the industry. ZEG outperforms 57.41% of its industry peers.
A Debt/Equity ratio of 0.61 indicates that ZEG is somewhat dependend on debt financing.
ZEG has a Debt to Equity ratio (0.61) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 5.85 |
ROIC/WACC1.6
WACC9%
2.3 Liquidity
A Current Ratio of 0.88 indicates that ZEG may have some problems paying its short term obligations.
ZEG's Current ratio of 0.88 is on the low side compared to the rest of the industry. ZEG is outperformed by 81.48% of its industry peers.
A Quick Ratio of 0.69 indicates that ZEG may have some problems paying its short term obligations.
With a Quick ratio value of 0.69, ZEG is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
ZEG shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.89%.
ZEG shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.59% yearly.
The Revenue has grown by 13.52% in the past year. This is quite good.
The Revenue has been growing by 17.27% on average over the past years. This is quite good.
EPS 1Y (TTM)4.89%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%-42.79%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
ZEG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.73% yearly.
The Revenue is expected to grow by 7.18% on average over the next years.
EPS Next Y13.8%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
EPS Next 5Y12.73%
Revenue Next Year9.58%
Revenue Next 2Y7.79%
Revenue Next 3Y7.12%
Revenue Next 5Y7.18%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 22.52, which indicates a rather expensive current valuation of ZEG.
Compared to the rest of the industry, the Price/Earnings ratio of ZEG is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 25.47, ZEG is valued at the same level.
ZEG is valuated correctly with a Price/Forward Earnings ratio of 16.85.
ZEG's Price/Forward Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.42, ZEG is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.52 | ||
| Fwd PE | 16.85 |
4.2 Price Multiples
ZEG's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. ZEG is more expensive than 64.81% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of ZEG indicates a slightly more expensive valuation: ZEG is more expensive than 64.81% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 57.9 | ||
| EV/EBITDA | 27.85 |
4.3 Compensation for Growth
ZEG's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ZEG has a very decent profitability rating, which may justify a higher PE ratio.
ZEG's earnings are expected to grow with 12.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.63
PEG (5Y)1.21
EPS Next 2Y13.64%
EPS Next 3Y12.91%
5. Dividend
5.1 Amount
ZEG has a Yearly Dividend Yield of 1.81%.
ZEG's Dividend Yield is comparable with the industry average which is at 3.01.
ZEG's Dividend Yield is slightly below the S&P500 average, which is at 2.44.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
52.89% of the earnings are spent on dividend by ZEG. This is a bit on the high side, but may be sustainable.
The dividend of ZEG is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
FRA:ZEG (11/19/2025, 7:00:00 PM)
154.25
+0.45 (+0.29%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap478.26B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target156.15 (1.23%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
Yearly Dividend2.56
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.51%
Min EPS beat(2)-49.27%
Max EPS beat(2)-1.74%
EPS beat(4)1
Avg EPS beat(4)-10.58%
Min EPS beat(4)-49.27%
Max EPS beat(4)9.32%
EPS beat(8)3
Avg EPS beat(8)-5.46%
EPS beat(12)7
Avg EPS beat(12)-1.7%
EPS beat(16)11
Avg EPS beat(16)0.58%
Revenue beat(2)0
Avg Revenue beat(2)-0.23%
Min Revenue beat(2)-0.24%
Max Revenue beat(2)-0.22%
Revenue beat(4)1
Avg Revenue beat(4)-0.43%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.08%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)0.82%
PT rev (3m)-0.13%
EPS NQ rev (1m)-1.05%
EPS NQ rev (3m)-0.73%
EPS NY rev (1m)0.05%
EPS NY rev (3m)1.17%
Revenue NQ rev (1m)-0.04%
Revenue NQ rev (3m)-0.26%
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)0.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.52 | ||
| Fwd PE | 16.85 | ||
| P/S | 9.53 | ||
| P/FCF | 57.9 | ||
| P/OCF | 36.59 | ||
| P/B | 12.07 | ||
| P/tB | N/A | ||
| EV/EBITDA | 27.85 |
EPS(TTM)6.85
EY4.44%
EPS(NY)9.15
Fwd EY5.93%
FCF(TTM)2.66
FCFY1.73%
OCF(TTM)4.22
OCFY2.73%
SpS16.19
BVpS12.78
TBVpS-3.77
PEG (NY)1.63
PEG (5Y)1.21
Graham Number44.38
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 5.85 |
F-Score7
WACC9%
ROIC/WACC1.6
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)4.89%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%-42.79%
EPS Next Y13.8%
EPS Next 2Y13.64%
EPS Next 3Y12.91%
EPS Next 5Y12.73%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year9.58%
Revenue Next 2Y7.79%
Revenue Next 3Y7.12%
Revenue Next 5Y7.18%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year34.36%
EBIT Next 3Y17.49%
EBIT Next 5Y13.09%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC / ZEG.DE FAQ
What is the fundamental rating for ZEG stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE.
What is the valuation status for ZEG stock?
ChartMill assigns a valuation rating of 3 / 10 to ASTRAZENECA PLC (ZEG.DE). This can be considered as Overvalued.
What is the profitability of ZEG stock?
ASTRAZENECA PLC (ZEG.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for ZEG stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC (ZEG.DE) is 22.52 and the Price/Book (PB) ratio is 12.07.
Can you provide the financial health for ZEG stock?
The financial health rating of ASTRAZENECA PLC (ZEG.DE) is 3 / 10.